Supply Chain

In the fourth part of his Pharma Commerce video interview, Sean O’Hearen, founder and principal consultant at 1st Line Partners, describes the prominence of underreporting falsified medicines.

In the fourth part of his Pharma Commerce video interview, Murray Aitken, executive director, IQVIA Institute for Human Data Science, outlines what he anticipates for the biosimilar adoption curve in key markets moving forward.

Pharma prepares for looming tariffs, as the US president signals a phased increase starting Aug. 1, but the official starting tax rate is yet to be determined.

In the third part of his Pharma Commerce video interview, Sean O’Hearen, founder and principal consultant at 1st Line Partners, recommends regulatory or verification mechanisms that can help safely legitimize online medicine procurement.

In the second part of his Pharma Commerce video interview, Sean O’Hearen, founder and principal consultant at 1st Line Partners, explains how the private sector should strategically support and scale efforts to ensure that HCPs globally receive substandard and falsified medicine detection training.

In the first part of his Pharma Commerce video interview, Sean O’Hearen, founder and principal consultant at 1st Line Partners, lays out the systemic gaps in medical and pharmacy education that need to be addressed, along with how academic and clinical institutions can accelerate awareness training in identifying substandard and falsified medicines.

The industry veteran will lead the company’s next phase of growth, focusing on faster treatment initiation through integrated digital platforms and optimized fulfillment strategies.

In the first part of his Pharma Commerce video interview, Murray Aitken, executive director, IQVIA Institute for Human Data Science, describes the process behind developing the “Global Use of Medicines Outlook Through 2029” report.

In the third part of this roundtable discussion, a panel of thought leaders explore the value of serialization, data sharing, and predictive analytics in identifying potential quality issues before they arise.

Through a strategic, non-profit agreement, Gilead will supply up to two million doses of the long-acting HIV prevention drug across 120 low- and lower-middle-income countries over the next three years.

The US president says the levies on pharmaceutical imports are imminent, but won’t take effect for a year to a year and a half.

The Craigavon investment enhances Almac’s global clinical supply network with upgraded storage, distribution, and shipping capabilities to meet the growing demand for temperature-sensitive medicines.

Amid the push for reshoring and fiscal reform, the tariffs are part of a broader effort to rebalance trade and fund domestic initiatives, as the pharma sector awaits potential levies of its own.

The company joins a wave of global pharma companies reshoring operations to strengthen the US supply chain and meet patient needs through domestic innovation and capacity.

The collaborative research initiative will be focused on advancing approaches to enhance the therapeutic efficacy of regulatory T cells and tumor-infiltrating lymphocytes.

The report spotlights China’s rapid biopharma advancement, alongside a GLP-1 surge, caution surrounding M&A, and a rise in biologics.

The new system meets the increasing demand for faster, more precise processes that enhance quality while boosting efficiency in the pharma manufacturing industry.

The 200,000 square-foot Madison, WI facility will serve as the flagship location, with capabilities for future growth.

Stay updated on the Drug Supply Chain Security Act as pharma stakeholders prepare for upcoming deadlines and improved data traceability.

Though this specific agreement centers around aerospace and automobiles, the greater supply chain will wait and see how Trump’s import taxes impact pharmaceuticals, a sector that faces a potential 25% tax on imports.

Approaches powered by RWD can clear the way for a greater focus on patient-centered care.

The biopharma company—whose US headquarters is in Atlanta—will be building a new biologics manufacturing facility in a city to be named at a later date.

The acquisition of Cryoport’s specialty courier business is now finalized, with a value of approximately $200 million.

In an effort to greater prepare HCPs and to avoid potential shortages, the company targets Q3 as the shipment date.

Potential import taxes on pharma goods entering the United States continue to have effects on the industry in more ways than one.